Bristol-Myers Squibb: Milvex Event Rates – May Get a Timing Update in NT – Incremental Positive if Pushed Based on Our Stats Analysis Simulation Scenario
Institutional-grade analysis used by equity desks before repricing events. 16 pages.
Report fact snapshot
- Publisher
- UBS
- Date
- 2026-06-11
- Type
- Market Report
- Region
- United States
- Sector
- Healthcare & Biotech
- Companies
- Bristol-Myers Squibb, Johnson & Johnson, Bayer, Novartis
- Key signal
- $5
Market is pricing this as noise.
Data shows a structural shift is underway.
Sector models are broken — re-rating is imminent.
Based on UBS research, June 2026 data and regional breakdowns
Key Signals
Market is pricing this as noise.
Data shows a structural shift is underway.
Why it matters: Identifies the exact point where consensus models diverge from actual data.
A re-rating catalyst is approaching.
Consensus has not yet reflected this shift.
Why it matters: Frames the catalyst window before violent repricing begins.
Winners are concentrated in this space.
Specific companies are structurally outperforming.
Why it matters: Tracks the capital rotation toward structural winners before it becomes consensus.
What You Gain From This Report
Decision Insight
Mispricing is not yet reflected in consensus models.
Missed Risk
Without the full report, you miss the company-level breakdown that separates winners from losers.
Timing Advantage
The catalyst window is open now — consensus repricing will close it within quarters.
What you miss without the full report:
- Company-level positioning and stock picks
- Valuation assumptions and model inputs
- Price target logic and catalyst timeline
Why Institutional Investors Care
Mispricing windows like this typically precede sector re-rating events.
Early positioning in structural winners often leads to outsized returns when consensus catches up.
The catalyst window narrows as monthly data becomes consensus, making near-term positioning critical.
Report Summary
UBS highlights that Bristol-Myers Squibb management may provide an updated timing for the milvexian Phase III AFib trial (LIBREXIA-AF) as early as the Q2 call. Based on UBS statistical analysis, if the trial timeline is pushed to early 2027, it would imply the hazard ratio is tracking at or below the non-inferiority cut-off of 1.13, increasing UBS's probability of success from 35-50% to 50-55%. Milvexian remains one of the key catalysts for BMY with $5-10B+ peak sales potential to offset Eliquis loss of exclusivity.
Institutional Content Below
Full PDF (16 pages), valuation models, broker logic, and detailed charts.
Key Takeaways
- If milvexian AFib trial timing is pushed to early 2027, it implies stroke HR is tracking below the 1.13 non-inferiority cut-off, which would be incrementally positive
- UBS raises probability of success (PoS) for stroke non-inferiority to 50-55% under the delayed-timing scenario, up from 35-50%
- Milvexian Phase III AFib data remains one of the major catalysts for BMY (with JNJ sharing economics), with $5-10B+ peak potential to offset Eliquis LOE
Topics Covered
Companies Mentioned
Who this summary is for
This summary is for users researching the UBS Bristol-Myers Squibb report. It helps users review Bristol-Myers Squibb: Milvex Event Rates – May Get a Timing Update in NT – Incremental Positive if Pushed Based on Our Stats Analysis Simulation Scenario coverage, key takeaways, and related broker or sector research paths across Milvexian Phase III AFib trial, Eliquis loss of exclusivity, Non-inferiority statistical analysis; Bristol-Myers Squibb, Johnson & Johnson.
Related Search Paths
Use these links to continue through broker, sector and report-type research summaries.
Request Full PDF Access
Get access to the full broker report, including company-level details, valuation assumptions, charts, and price target logic.
Access is provided through VIP service or request confirmation.